Skip to content
Screener

Generate Biomedicines, Inc. GENB Enterprise value

Enterprise value at other companies

Southern Company logo
Southern CompanySO
$182.31B—
Semtech logo
SemtechSMTC
$10.14B+243%
Synopsys logo
SynopsysSNPS
$103.09B+59.9%
AutoZone logo
AutoZoneAZO
$60.42B-18.0%
Nucor logo
NucorNUE
$36.42B+47.2%
Northern Trust logo
Northern TrustNTRS
$26.46B+62.4%

Other financials

Income statement

See full
Revenue$6.3M-37.7%
Operating income-$71.6M-19.1%
Net income-$67.3M-28.3%
EPS (diluted)-$0.52+73.2%

Balance sheet

See full
Cash & equivalents$135.4M-12.3%
Total debt$62.6M—
Total equity$456.0M+188%
Total assets$561.7M—

Cash flow

See full
Operating cash flow-$57.9M-18.9%
CapEx$933.0K+506%
Free cash flow-$58.9M-20.4%

Valuation

See full
Market cap$1.86B+19.8%
P/S57.2×—

Profitability

See full
Operating margin-751.2%—
Net margin-685.9%—
FCF margin-756.9%—

Returns & leverage

See full
Return on equity2,979.4%—
Debt / equity0.1×—
Current ratio8.3×—

Where this comes from

Calculated from Generate Biomedicines, Inc.’s reported figures.

$2.2Bmarket cap+$62.6Mtotal debt−$135.4Mcash and equivalents=$2.09B

The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 6:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336437

FAQ

What is Generate Biomedicines, Inc.'s enterprise value?
Generate Biomedicines, Inc. (GENB) reported enterprise value of $2.09B in Q2 2026.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about Generate Biomedicines, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude